Juvenile spondyloarthritis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:30:39 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Juvenile spondyloarthritis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Ixekizumab and Adalimumab for Children with Juvenile Idiopathic Arthritis, Including Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis https://clinicaltrials.eu/trial/study-of-ixekizumab-and-adalimumab-for-children-with-juvenile-idiopathic-arthritis-including-enthesitis-related-arthritis-and-juvenile-psoriatic-arthritis/ Wed, 29 Apr 2026 14:26:26 +0000 https://clinicaltrials.eu/trial/study-of-ixekizumab-and-adalimumab-for-children-with-juvenile-idiopathic-arthritis-including-enthesitis-related-arthritis-and-juvenile-psoriatic-arthritis/ This clinical trial is focused on studying two types of juvenile idiopathic arthritis: Enthesitis-related arthritis and Juvenile psoriatic arthritis. These are conditions that cause joint pain and swelling in children. The study will use two treatments: Ixekizumab and Adalimumab. Ixekizumab is a medication that helps reduce inflammation by targeting specific proteins in the body, while Adalimumab, also known by code names like ABP 501, is another treatment that works similarly to reduce joint inflammation.

The purpose of the study is to evaluate how effective Ixekizumab is in treating these types of arthritis in children. The study will involve giving the medications through a subcutaneous injection, which means the medicine is injected under the skin. Children participating in the study will receive either Ixekizumab or Adalimumab, and their progress will be monitored over time to see how well the treatments work in reducing symptoms of arthritis.

Throughout the study, researchers will observe the safety and tolerability of the treatments, ensuring that they are safe for use in children. The study aims to provide valuable information on how these medications can help manage juvenile idiopathic arthritis, potentially improving the quality of life for children affected by these conditions.

]]> Study on the Safety and Body Processing of Bimekizumab in Children with Juvenile Idiopathic Arthritis https://clinicaltrials.eu/trial/study-on-the-safety-and-body-processing-of-bimekizumab-in-children-with-juvenile-idiopathic-arthritis/ Wed, 29 Apr 2026 14:23:06 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-body-processing-of-bimekizumab-in-children-with-juvenile-idiopathic-arthritis/ This clinical trial is focused on studying certain types of juvenile idiopathic arthritis, specifically enthesitis-related arthritis (which includes juvenile-onset ankylosing spondylitis) and juvenile psoriatic arthritis. These are conditions that cause joint inflammation in children and can lead to pain and stiffness. The treatment being studied is a medication called bimekizumab, which is given as a solution for injection under the skin. Bimekizumab is also known by its code name, UCB4940.

The purpose of this study is to learn if bimekizumab is safe and how it moves throughout the body in children with these types of arthritis. The study will involve children aged 2 to less than 18 years who have active disease. Participants will receive bimekizumab injections and will be monitored over a period of time to see how the medication affects them. The study will also look at any side effects that may occur and how the children’s health changes during the study.

Throughout the study, researchers will measure the levels of bimekizumab in the blood and observe any changes in the participants’ health, including their growth and vital signs like blood pressure and heart rate. The study will also assess any reactions at the injection site and monitor for any serious side effects, such as infections or other health issues. This information will help determine the safety and effectiveness of bimekizumab for treating these types of juvenile arthritis in children.

]]>